Revenue: As of FY2026 Q1, the actual value is USD 14.82 M, beating the estimate of USD 14.5 M.EPS: As of FY2026 Q1, the actual value is USD 0.09.EBIT: As of FY2026 Q1, the actual value is USD 631.92 K.<h4>Q1 2026 Financial Highlights (Year-over-Year Improvements)</h4><ul><li>Revenue From Continuing Operations: Increased by 13%.</li><li>Adjusted EBITDA From Continuing Operations: Improved by +$2.2 million.</li><li>Net Income From Continuing Operations: Increased by +$1.6 million.</li><li>Free Cash Flow: Improved by +$2.3 million.</li><li>Cash Flow from Operating Activities: Improved by $2.2 million.</li></ul><h4>Q1 2026 Operating Metrics</h4><ul><li>System-wide Sales: Totaled $126.1 million, a decrease of -4.9% compared to Q1 2025.</li><li>Comp Sales: Decreased by -4.2% compared to Q1 2025.</li><li>Consolidated Adjusted EBITDA: Reached $3.5 million, an increase of 22% compared to Q1 2025.</li><li>Total Clinics Open: 943 at quarter-end Q1 2026.</li></ul><h4>Detailed Financials (Three Months Ended March 31, 2026 vs. 2025)</h4><ul><li>Revenue: $14.8 million in Q1 2026, up from $13.1 million in Q1 2025, a difference of +$1.7 million.</li><li>Cost of Revenues: $2.7 million in Q1 2026, down from $3.0 million in Q1 2025, a difference of -$0.3 million.</li><li>Selling and Marketing: $3.7 million in Q1 2026, up from $3.5 million in Q1 2025, a difference of +$0.2 million.</li><li>G&amp;A Expenses: $7.1 million in Q1 2026, up from $6.9 million in Q1 2025, a difference of +$0.2 million.</li><li>Net Income from Continuing Operations: $1.1 million in Q1 2026, up from -$0.5 million in Q1 2025, a difference of +$1.6 million.</li><li>Consolidated Net Income: $1.3 million in Q1 2026, up from $1.0 million in Q1 2025, a difference of +$0.3 million.</li><li>Consolidated Adjusted EBITDA: $3.5 million in Q1 2026, up from $2.9 million in Q1 2025, a difference of +$0.6 million.</li><li>Cash Flows Used in Operating Activities: -$1,476,170 in Q1 2026, an improvement from -$3,700,654 in Q1 2025.</li><li>Free Cash Flow: -$1,710,770 in Q1 2026, an improvement from -$4,032,159 in Q1 2025.</li></ul><h4>Capital Allocation and Refranchising</h4><ul><li>The Joint Corp. signed an Asset Purchase Agreement in April 2026 for the sale of 45 corporate-owned or managed clinics for $2.3 million.</li><li>A Letter of Intent for the sale of five additional corporate-owned or managed clinics was made in Q1 2026, which will leave only three company-owned clinics remaining after these agreements.</li><li>The company repurchased 137,000 shares for $1.1 million during Q1 2026, at an average price of $8.35 per share, with $4.5 million remaining on the share repurchase plan.</li><li>Recent buybacks of three Regional Developer (RD) territories are expected to reduce RD royalties by approximately $450,000 on an annualized basis.</li><li>Unrestricted cash stood at $20.7 million as of March 31, 2026.</li></ul><h4>Credit Agreement Amendment and Covenants</h4><ul><li>On May 1, 2026, The Joint Corp. entered into a waiver and fourth amendment to its existing credit agreement, addressing an existing default due to a violation of its fixed charge coverage ratio covenant for the fiscal quarter ending December 31, 2025.</li><li>The revolving credit maturity date has been extended to August 31, 2029.</li><li>The fixed charge coverage ratio definition was amended, reducing the amount of Restricted Payments subtracted in the ratio calculation by up to $10,000,000 for Q1-Q3 2026 and up to $5,000,000 for Q4 2026.</li><li>A new covenant requires The Joint Corp. to maintain a minimum liquidity of not less than $10,000,000 at any time during the period from January 1, 2026, to December 31, 2026.</li></ul><h4>Outlook / Guidance</h4>The Joint Corp. reiterated its 2026 guidance, expecting system-wide sales between $519 million and $552 million, and consolidated Adjusted EBITDA between $12.5 million and $13.5 million. The company anticipates comp sales to range from -3% to 3% and projects 30 to 35 new franchised clinic openings. Management expects comp sales trends to improve throughout the balance of 2026.

JOINT | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.82 M